Empowering Oncology: KORU Medical Systems Enhances Drug Delivery
KORU Medical Systems Enhances Infusion Experience for Nurses and Patients
KORU Medical Systems, Inc. (NASDAQ: KRMD), renowned for its innovative medical solutions, has recently unveiled fascinating data regarding its FreedomEdge® Infusion System. Designed for large-volume subcutaneous infusion, this system garnered high praise from nursing staff in a study that highlighted its advantages over traditional manual syringe administration in clinical settings.
Key Findings from the Nursing Preference Study
The Nursing Preference Study, which involved nurses across multiple hospitals, aimed to evaluate several critical aspects of drug administration. The focus was on the time nurses spend with patients, the impact on both nursing and patient comfort, and the overall preference for using modern infusion technology versus conventional methods.
Patient Interaction Improvement
One of the most striking results was that 97% of nurses reported an increase in patient interaction when using the KORU FreedomEdge® Infusion System. This enhancement is particularly valuable in oncology, where meaningful patient engagement can significantly influence care outcomes and patient satisfaction.
Reduction in Discomfort for Nurses
Moreover, 81% of nurses noted a reduction in hand pain, a common complaint during manual syringe administration. The ease of using the FreedomEdge® System not only improves efficiency but also helps in reducing nurse fatigue and discomfort, impacting job satisfaction positively.
Ease of Use is a Game Changer
Ease of use was another compelling advantage of the FreedomEdge® System, with 91% of nurses finding it simpler and quicker to set up compared to traditional methods. This aspect allows nurses to focus more on patient care rather than on complex administration procedures.
Improved Patient Comfort
From a patient perspective, 73% of nurses observed that patients experienced less pain during infusions with the FreedomEdge® System. This improvement in patient comfort is essential, especially in oncology care where treatment can be taxing on patients.
The Trend Towards Subcutaneous Oncology Drug Delivery
The shift from intravenous to subcutaneous delivery methods for oncology drugs is gaining traction among pharmaceutical manufacturers. Current estimates indicate that over one million global infusions are anticipated for five biologic oncology drugs that have received approval for in-clinic administration.
This growing trend signifies a major development in how patients receive treatment, leading to simpler protocols and improved quality of life. With advancements in subcutaneous therapies, KORU Medical’s FreedomEdge® Infusion System creates opportunities for more efficient drug administration methods.
Insights from Leadership
Linda Tharby, President and CEO of KORU Medical, expressed her enthusiasm for the study's findings. She emphasized that the increasing use of large-volume subcutaneous oncology drugs presents operational challenges, particularly with manual methods that require extensive nurse involvement.
Ms. Tharby stated, “KORU’s FreedomEdge® System provides an effective solution to these challenges, enhancing the drug delivery experience for both nurses and patients. We are excited about the positive reception from nursing professionals and are looking forward to submitting for FDA clearance with an oncology biologic in the near future.”
About KORU Medical Systems
KORU Medical focuses on developing innovative solutions that enhance the quality of life for patients globally. Their product lineup includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, which enable easier self-administration and less stressful administration procedures for healthcare professionals.
By providing advanced subcutaneous infusion systems, KORU Medical supports both patients and healthcare providers, aiming for improvements in treatment efficacy and comfort. If you want to learn more about their offerings, check out www.korumedical.com.
Frequently Asked Questions
What was the focus of KORU's recent study?
The study aimed to evaluate nursing preferences between the KORU FreedomEdge® Infusion System and manual syringe administration during oncology infusions.
What percentage of nurses preferred the FreedomEdge® System?
97% of nurses indicated a preference for the KORU FreedomEdge® Infusion System over manual syringe methods, citing ease of use and patient comfort.
How did the FreedomEdge® System affect patient interaction?
Nurses reported having more time for patient interaction when using the FreedomEdge® System than manual methods, enhancing the overall patient experience.
What impact did the FreedomEdge® System have on nurse discomfort?
81% of nurses reported reduced discomfort and hand pain while using the FreedomEdge® System compared to manual administration.
What innovations does KORU Medical offer?
KORU Medical specializes in large volume subcutaneous infusion solutions, focusing on enhancing treatment experiences for patients and healthcare professionals alike.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Recent Articles
- Cohu's Innovative Neon Platform Revolutionizes HBM Market
- Bectran's Innovative Solutions Shine in Construction Tech Awards
- Phibro Animal Health's Major Acquisition Enhances Product Portfolio
- Open Banking Market Expected to Surge with AI Innovations
- Explore Luxury Living: First Condominiums at The Emory
- S&W Seed Company Announces Fiscal Year 2024 Financial Highlights
- EnerSys Launches Innovative ABSL Battery for NASA Mission
- Runway Growth Capital Joins Forces with BC Partners Credit
- Bristol Myers Squibb Showcases COBENFY Data at Psych Congress
- Revolutionary Partnership to Transform Cleaning Solutions Globally
- Boeing's Strategic Shift: Dismantling Diversity Department
- UNITE HERE Enhances Hotel Monitoring with AI Review Insights
- Floor & Decor Expands Its Presence with New Beaverton Store
- Manitowoc's Q3 2024 Earnings Call: Navigating Market Challenges
- AI Innovations Driving Growth in Hypothyroidism Market
- Projected Growth in the Arts and Crafts Market Through 2028
- Enviri Corp's Earnings Call Highlights Mixed Results for Q3
- BETA Technologies Secures $318 Million for Future Innovations
- Celebrate Halloween with IPX1031’s Special Video Release
- Flow Beverage Secures $2 Million in Convertible Debt Expansion
